There are now seven FDA-approved GLP-1-based medications on the market, each with its own dosing schedule and use case: Ozempic and Rybelsus (semaglutide) originally approved for type 2 diabetes Wegovy (semaglutide, higher dose) approved specifically for chronic weight management Mounjaro (tirzepatide) a dual GLP-1/GIP agonist approved for diabetes Zepbound (tirzepatide) the weight-loss version of Mounjaro Trulicity and Victoza (dulaglutide and liraglutide) older, well-established options with long safety track records Clinical trial data shows Zepbound and Mounjaro, which act on two different gut hormone receptors instead of one, tend to produce the most dramatic results, with some participants losing between 15% and 22% of their total body weight over the course of a trial
One drug doesnt fix everything
Every time you eat, breathe, or move, your body uses fuel created from the food you eat to produce energy
To pursue the tanning agent, melanotan-I was licensed by Competitive Technologies, a technology transfer company operating on behalf of University of Arizona, to an Australian startup called Epitan, [12] [11] which changed its name to Clinuvel in 2006